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Background: Hormone-refractory prostate cancer (HRPC), which is resistant to hormone therapy, is a major obstacle in
clinical treatment. An approach to inhibit HRPC growth and ultimately to kill cancers is highly demanded.
Results: KUD773 induced the anti-proliferative effect and subsequent apoptosis in PC-3 and DU-145 (two HRPC
cell lines); whereas, it showed less active in normal prostate cells. Further examination showed that KUD773 inhibited
tubulin polymerization and induced an increase of mitotic phosphoproteins and polo-like kinase 1 (PLK1)
phosphorylation, indicating a mitotic arrest of the cell cycle through an anti-tubulin action. The kinase assay
demonstrated that KUD773 inhibited Aurora A activity. KUD773 induced an increase of Cdk1 phosphorylation at
Thr161 (a stimulatory phosphorylation site) and a decrease of phosphorylation at Tyr15 (an inhibitory phosphorylation
site), suggesting the activation of Cdk1. The data were substantiated by an up-regulation of cyclin B1 (a Cdk1 partner).
Furthermore, KUD773 induced the phosphorylation and subsequent down-regulation of Bcl-2 and activation of caspase
cascades.
Conclusions: The data suggest that KUD773 induces apoptotic signaling in a sequential manner. It inhibits tubulin
polymerization associated with an anti-Aurora A activity, leading to Cdk1 activation and mitotic arrest of the cell cycle
that in turn induces Bcl-2 degradation and a subsequent caspase activation in HRPCs.
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Mitochondria-involved apoptosisBackground
The anticancer agents that act on different cellular tar-
gets may result in an arrest of the cell cycle at particular
phase. Tubulin-targeting agents inhibit normal function of
mitotic spindle, leading to a halt of the cell cycle at mitotic
phase and a subsequent cell death [1-3]. Currently,
tubulin-targeting agents have been successfully used in
cancer chemotherapy against several types of cancers,
including breast cancer, ovarian cancer and hormone-
refractory prostate cancer (HRPC) [1,4,5]. However, the
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unless otherwise stated.and neutropenia, limit the effectiveness of tubulin-
targeting agents [3,6]. Accordingly, a novel approach
that reduces toxic effect but reserves the activity to
trigger mitotic arrest and cell death can be helpful in
cancer chemotherapy.
Aurora A kinase, belonging to a family of mitotic
serine/threonine kinase, is implicated with critical pro-
cesses in cell mitosis [7]. The regulation of Aurora A
RNA, protein and kinase activity is dependent of cell cycle
with peaking in the transition of G2 to mitotic phase [8].
Aurora A participates in centrosomal separation, forma-
tion of bipolar spindle and attachment of chromosomal
kinetochore to mitotic spindle [8,9]. Several lines of
evidence show that Aurora A is overexpressed in a wide
variety of types of cancers, including hepatocellularis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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atic cancer [10-12]. Frequent activation/overexpression
of Aurora A in human primary prostate cancers has
been reported. Furthermore, constitutive Aurora A acti-
vation displays higher oncogenic activity [13,14]. Acti-
vation/overexpression of Aurora A has been suggested
to override mitotic spindle assembly checkpoint, lead-
ing to the resistance to taxol-induced apoptosis [3,15].
Moreover, it overrides cytotoxic agents-mediated down-
regulation of Bcl-2 and Bcl-xL and decreased NF-κB activ-
ity [16,17], indicating that Aurora A plays a crucial role in
addition to cell cycle regulation. These studies suggest that
Aurora A can be a potential target for the development of
cancer chemotherapeutic drugs.
HRPC occurs when hormone therapy fails to prevent
the cancer growth for any longer. Advance prostate can-
cer often spreads to other parts of the body, including
lymph nodes and bones. Therefore, HRPC is a treatment
dilemma for practicing physician. Chemotherapy is one
of the major choices for HRPC treatment. However,
drug resistance developed in cancer cells is always a key
concern in cancer chemotherapy. Imidazoles and thia-
zoles have been widely discovered as fundamental com-
ponents of structurally diverse natural products that
display a variety of activities, such as anticancer and
antiviral activities [18-20]. The excellent pharmacological
activities based on the azole skeletons have led to the
generation of a lot of chemically synthetic compounds
and have directed novel therapeutic applications [21].
To search for potential anticancer compounds against
HRPCs, we have synthesized a series of derivatives based
on thiazoles and imidazoles heterocycles. KUD773,
2-(1H-imidazol-1-yl)-4-(3-(trifluoromethyl)phenyl)thiazole
[22], stood out and demonstrated anti-proliferative as well
as apoptotic activities in PC-3 and DU-145, two HRPC
cell lines. The study has characterized the anticancer
activity and the mechanism of action of KUD773. The
inhibition of tubulin polymerization and Aurora A activity
has been delineated and the downstream signaling cascade
has been studied in HRPCs.
Methods
Materials
RPMI 1640 medium and fetal bovine serum (FBS) were
obtained from GIBCO/BRL Life Technologies (Grand
Island, NY). Antibodies to poly ADP ribose polymerase
(PARP), caspase-7, Bcl-2, Bak, Bax, Bad, Mcl-1, and
anti-mouse and anti-rabbit IgGs were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-
bodies to actin, cyclin B1, cyclin A, caspase-9, caspase-8,
phosphorylated cyclin dependent kinase-1 (cdk1) at
Tyr15, p-cdk1Thr161, phosphorylated polo-like kinase 1
(PLK1) at Thr210, matrix metalloprotease-2 (MMP-2),
MMP-9, p-histone H3Ser10, acetyl-histone H3, p-H2A.XSer139 (γ-H2A.X) and GAPDH were from Cell Signaling
Technologies (Boston, MA). The antibody to caspase-3
was from Imgenex, Corp. (San Diego, CA). The antibodies
to β-tubulin and mitotic protein monoclonal 2 (MPM-2)
were from BD Biosciences PharMingen (San Diego, CA)
and Upstate Biotechnology (Lake Placid, NY), respectively.
Sulforhodamine B (SRB), taxol, vincristine, carboxyfluo-
rescein succinimidyl ester (CFSE), 4,6-diamidino-2-pheny-
lindole dihydrochloride (DAPI), propidium iodide (PI) and
all other chemical compounds were obtained from Sigma-
Aldrich (St. Louis, MO). KUD773 (Figure 1A) was
synthesized with the purity of more than 98% by the
examination using 1H and 13C NMR and elemental
analysis (C, H, N, S) [22].
Tissue explants and cell culture
All human tissue samples were obtained following in-
formed consent of the donors and after full review by the
Ethics Review Committee at National Taiwan University
Hospital. Human prostate specimens were from males by
transurethral resection of the prostate in National Taiwan
University Hospital. All patients with prostatism histories
were diagnosed to have benign prostate hyperplasia by
rectal digital examination, transrectal sonography of pros-
tate and urodynamic studies. Isolation of human prostatic
cells from prostatic tissue explants was described in the
previous study [23]. The HRPC cell lines, PC-3 and
DU-145, were obtained from American Type Culture
Collection (Rockville, MD). The cells were cultured in
RPMI1640 medium with 10% FBS (v/v) and penicillin
(100 units/ml)/streptomycin (100 μg/ml). Cultures were
maintained in a humidified incubator at 37°C in 5%
CO2/95% air.
SRB assay
Cells were seeded in 96-well plates in medium with 5%
FBS. After 24 h, cells were fixed with 10% trichloroacetic
acid (TCA) to represent cell population at the time of
compound addition (T0). After additional incubation of
0.1% dimethylsulfoxide (DMSO) or KUD773 for 48 h,
cells were fixed with 10% TCA and SRB at 0.4% (w/v) in
1% acetic acid was added to stain cells. Unbound SRB
was washed out by 1% acetic acid. SRB bound cells were
solubilized with 10 mM Trizma base. The absorbance
was read at a wavelength of 515 nm. Using the following
absorbance measurements, such as time zero (T0), control
growth (C), and cell growth in the presence of KUD773
(Tx), the percentage growth was calculated at each of the
compound concentrations levels. Percentage growth in-
hibition was calculated as: [1- (Tx-T0)/(C-T0)] × 100%.
Growth inhibition of 50% (GI50) is determined at the com-
pound concentration which results in 50% reduction of
total protein increase in control cells during the com-
pound incubation [24].
Figure 1 Chemical structure of KUD773 and identification of
anti-proliferative effect. (A) Chemical structure of KUD773. (B) After
the treatment with or without KUD773 for 48 h, the cells were fixed
and stained with SRB and the data were analyzed. (C) PC-3 cells were
labeled with CFSE and treated with vehicle or KUD773 (3 μM). The
fluorescence intensity was determined by flow cytometric analysis.
Data are expressed as mean ± SEM of three determinations. *P < 0.05
and **P < 0.01 compared with the respective control.
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The cells were adjusted to a density of 106 cells/ml and
were treated with CFSE at a final concentration of
10 μM. After incubation at 37°C for 10 min, labeling was
blocked by the addition of RPMI medium with 10% FBS.
Tubes were placed in ice for 5 min and then washed.
After centrifugation, the cells were seeded in RPMI
medium with 10% FBS for 24, 48 and 72 h at 37°C under5% CO2/95% air. After the treatment, the fluorescence
intensity was determined by flow cytometric analysis.Flow cytometric analysis of PI staining
After the treatment of cells with vehicle (0.1% DMSO) or
KUD773 for the indicated times, the cells were harvested
by trypsinization, fixed with 70% (v/v) alcohol at 4°C for
30 min and washed with phosphate-buffered saline (PBS).
After centrifugation, cells were incubated in 0.1 M of
phosphate-citric acid buffer (0.2 M NaHPO4, 0.1 M citric
acid, pH7.8) for 30 min at room temperature. Then, the
cells were centrifuged and resuspended with 0.5 ml PI
solution containing Triton X-100 (0.1% v/v), RNase (100
μg/ml) and PI (80 μg/ml). DNA content was analyzed with
the FACScan and CellQuest software (Becton Dickinson,
Mountain View, CA).Western blotting
After the indicated exposure time to DMSO or KUD773,
the cells were washed twice with ice-cold PBS and reac-
tion was terminated by the addition of 100 μl ice-cold
lysis buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl,
1 mM EGTA, 1 mM phenylmethanesulfonyl fluoride
(PMSF), 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1%
Triton X-100). For western blot analysis, the amount of
proteins (40 μg) were separated by electrophoresis in a
10% polyacrylamide gel and transferred to a nitrocellu-
lose membrane. After an overnight incubation at 4°C in
PBS/5% nonfat milk, the membrane was washed with
PBS/0.1% Tween 20 for 1 h and immuno-reacted with
the indicated antibody for 2 h at room temperature.
After four washings with PBS/0.1% Tween 20, the anti-
mouse or anti-rabbit IgG (dilute 1:2000) was applied
to the membranes for 1 h at room temperature. The
membranes were washed with PBS/0.1% Tween 20 for
1 h and the detection of signal was performed with an
enhanced chemiluminescence detection kit (Amersham).Microtubule assembly assay
After the treatment with the indicated agent for 24 h, the
cells were harvested by trypsinization and collected by
centrifugation. The cells were lysed with 0.1 ml of hypo-
tonic buffer (1 mM MgCl2, 2 mM EGTA, 0.5% NP-40,
2 mM PMSF, 200 U/ml aprotinin, 100 μg/ml soybean
trypsin inhibitor, 5.0 mM ε-amino caproic acid, 1 mM
bezamidine and 20 mM Tris–HCl, pH 6.8). The cytosolic
and cytoskeletal fraction of cell lysate were separated by
centrifugation at 16,000×g for 15 min. The supernatant
contained cytosolic tubulin. The pellet representing the
particulate fraction of polymerized tubulin was resus-
pended in 0.1 ml hypotonic buffer. Tubulin contents in
both fractions were detected by Western blotting.
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Cells were seeded in 8-well chamber slides. After the
compound treatment for 12 h, the cells were fixed with
100% methanol at −20°C for 5 min and incubated in 1%
bovine serum albumin (BSA) containing 0.1% Triton X-
100 at 37°C for 30 min. The cells were washed twice
with PBS for 5 min and stained with anti-β-tubulin or
anti-γ-tubulin antibody at 37°C for 1 h and then, the
FITC-conjugated secondary antibody at 37°C for 40 min.
Nuclear staining was performed by 1 μg/ml DAPI. The
cells were analyzed by a confocal laser microscopic sys-
tem (Leica TCS SP2).
Aurora A luminescent kinase assay
Test compounds, enzyme and substrate-tetra (LRRWSLG)/
dithiothreitol (DTT)/ATP mix were dissolved in Aur
assay buffer (50 mM Tris–HCl pH 7.4, 10 mM NaCl,
10 mM MgCl2,100 μg/ml BSA) separately before the
assay. Twenty five μl of test compounds in DMSO
stock solution and 10 μl enzyme were added into 96
well U-bottomed plate (268152, NUNC, Rochester, NY),
and incubated at 25°C for 15 min. Fifteen μl substrate/
DTT/ATP mix was added into the plate to initiate the
assay. The assays was carried out at 37°C for 90 min in a
final volume of 50 μl including the following components:
50 mM Tris–HCl pH 7.4, 10 mM NaCl, 10 mM
MgCl2,100 μg/ml BSA, 1 mM DTT, 15 μM peptide sub-
strate, 5 μM ATP, 90 ng/well Aurora A kinase, and test
compound. A volume (50 μl) of Kinase-Glo Plus Reagent
(Promega) was added into the completed kinase reaction,
followed by incubation at 25°C for 20 min. Seventy μl of
reaction mixture was transferred to 96 well black plate
and luminescence was recorded by vector2 V (1420 mul-
tilable HTS counter, Perkin Elmer, Shelton, CT).
Data analysis
Data are presented as the mean ± SEM for the indicated
number of separate experiments. Student’s t-test is ap-
plied for comparison of two groups. P-values less than
0.05 are statistically considered significant.
Results
Determination of anti-proliferative activity of KUD773
The effect of KUD773 on cell proliferation was exam-
ined using SRB assay based on the measurement of cel-
lular protein content. The data demonstrated that
KUD773 exhibited a higher activity against prostate can-
cer PC-3 (GI50 = 1.7 μM) and DU-145 (GI50 = 3.2 μM)
than primary human prostate cells (GI50 = 18.3 μM)
(Figure 1B). The anti-proliferative activity was further
confirmed by flow cytometric analysis of CFSE-staining
assay. After the conjugation with cellular proteins, CFSE
labeling is allocated evenly to daughter cells after cell div-
ision. The fluorescence intensity is decreased thereafter.The data in Figure 1C demonstrated a doubling time
of 30.2 h in vehicle-treated PC-3 cells. The exposure of
KUD773 (3 μM) significantly inhibited the decrease of
fluorescence intensity showing a doubling time of 53.4 h
(Figure 1C).
Effect of KUD773 on the progression of cell cycle in PC-3
cells
Cellular stresses may cause the arrest of cell cycle at par-
ticular phase, leading to the inhibition of cell proliferation.
The effect of KUD773 on the progression of cell cycle was
examined by flow cytometric analysis of PI staining with
DNA. As a consequence, KUD773 induced an arrest of
the cell cycle at G2/M phase in a time-dependent fashion
and a subsequent increase of hypodiploid sub-G1 phase
(apoptosis) (Figure 2). The progression of cell cycle is reg-
ulated by cyclins and the binding partner Cdks. Cyclin A/
Cdk2 complex activity tightly regulates S phase and G2
phase. In contrast, cyclin B1/Cdk1 complex controls the
progression from G2- to M-phase [25]. The exposure of
cells to KUD773 resulted in down-regulation of cyclin A
while up-regulation of cyclin B1 in PC-3 cells (Figure 3).
The effect was associated with an increased phosphoryl-
ation of Cdk1 at Thr161 (a stimulatory phosphorylation
site) and a concomitant decreased phosphorylation at
Tyr15 (an inhibitory phosphorylation site) (Figure 3), sug-
gesting the activation of Cdk1 [26]. Additionally, the de-
tection of a dramatic increase of mitotic phosphoproteins
using antibody to MPM-2 showed that KUD773 induced
a mitotic arrest of the cell cycle in PC-3 cells (Figure 3).
PLK1 activity, another cell cycle regulator, is altered at dif-
ferent mitotic stages through the phosphorylation at
Thr210. The phosphorylation peaks in prometaphase and
gradually disappears in anaphase [27]. KUD773 main-
tained a high level of PLK1 phosphorylation at Thr210 in
PC-3 cells (Figure 3) indicating that KUD773 induced the
mitotic arrest at prometaphase to metaphase. Similar data
were also detected in DU-145 cells (Figure 4).
Effect of KUD773 on inhibition of microtubule assembly
and formation of monopolar spindle
Several cellular stresses, including disturbance of micro-
tubule dynamics and inhibition of Aurora A during mi-
tosis, have been suggested to induce mitotic arrest of the
cell cycle [28,29]. To determine whether tubulin/micro-
tubule served as a target for KUD773, the microtubule
assembly assay was performed which the assembly and
disassembly microtubules in particulate and soluble frac-
tions, respectively, were separated. As a result, the micro-
tubule assembly (particulate fraction) was decreased in the
presence of KUD773 and vincristine (positive control).
In contrast, taxol increased the microtubule assembly
(Figure 5A). Interestingly, KUD773 induced the forma-
tion of monopolar spindle with 12.7 ± 1.1%, 37.8 ± 6.2%
Figure 2 Effect of KUD773 on cell cycle progression and apoptosis. PC-3 cells were treated without or with KUD773 (3 μM) for the indicated
times. Then, the cells were fixed and stained with PI to analyze DNA content by flow cytometric analysis. Data are expressed as mean ± SEM of
three determinations. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the zero time control.
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(Figure 5B). The effective concentration for 50% formation
(EC50) was 26.2 μM. The data of γ-tubulin staining also
showed the formation of monopolar spindle (Figure 5C).
Several lines of evidence reveal that the deficiency of
Aurora A activity leads to the failure in centrosomal
duplication or centrosomal separation, producing amonopolar spindle array [30,31]. In this study, Aurora A
luminescent kinase assay was performed. The data showed
that KUD773 inhibited Aurora A in a concentration-
dependent manner with an IC50 of 30.0 μM (Figure 5D),
which was similar to the induction of monopolar spindle
formation, indicating that the anti-Aurora A activity might
partly contribute to the formation of monopolar spindle.
Figure 3 Effect of KUD773 on the expressions of several cell-cycle
regulators. PC-3 cells were incubated in the absence or presence of
KUD773 (3 μM) for various times. Cells were harvested and lysed for the
detection of the indicated protein expression by Western blot. The
expression was quantified using the computerized image analysis
system ImageQuant (Amersham Biosciences). The images are
representative of three independent experiments. The data are
expressed as mean ± SEM of three to four independent experiments.
*P < 0.05, **P < 0.01 and ***P < 0.001 compared with the control
of 100%.
Figure 4 Effect of KUD773 on the expression of several proteins
in DU-145 cells. The cells were incubated in the absence or presence
of KUD773 (3 μM) for various times. Cells were harvested and lysed for
the detection of the indicated protein expression by Western blot. The
images are representative of two independent experiments.
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proteins and caspase cascades
Bcl-2 family proteins play a central role on regulating
the integrity of mitochondrial membrane and caspase-
mediated apoptotic cell death. Several pro-apoptotic mem-
bers in this family, including Bax, Bak and Bad, promote
the release of cytochrome c and other proteins through
the outer mitochondrial membrane. Some members, such
as Bcl-2 and Mcl-1, are able to antagonize pro-apoptotic
members and to keep mitochondrial integrity [32,33]. Inthis regard, KUD773 induced a profound increase of Bcl-2
phosphorylation followed by a significant decrease of Bcl-
2 protein expression in PC-3 cells. In contrast, KUD773
did not modify the protein levels of the other members,
including Mcl-1, Bax, Bak and Bad (Figure 6A). Bcl-
2 phosphorylation, a biochemical marker for tubulin-
targeting agents [34], also supported that KUD773 acted
on tubulin for the execution of anticancer function.
Next, the activation of caspase proteases was examined
by Western immunoblot analysis. Caspases were synthe-
sized primarily as inactive precursors. As demonstrated in
Figure 6B, the caspases were present as un-cleaved forms
in untreated cells. After the exposure to KUD773, the
cleavage of inactive precursors to active fragments was de-
tected, in particular, at the 24-h and 48-h treatment. The
cleavage of PARP-1, a preferred substrate for caspase-3
and caspase-7, was also apparent to KUD773 action
(Figure 6B). The data reveal that the caspase activation is
responsible for KUD773-mediated apoptotic cell death.
Effect of KUD773 on the expression levels of MMP-2 and
MMP-9
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are
cancer-associated zinc-dependent endopeptidases. Both
Figure 5 Effect of KUD773 on microtubule assembly assay. (A) PC-3 cells were incubated in the absence or presence of the indicated agent
(taxol, 0.1 μM; vincristine, 0.1 μM). The cells were harvested and separated into soluble (S, microtubule disassembly) and particulate form
(P, microtubule assembly), and proteins were detected by Western blot analysis. The data for relative expression of particulate fraction are also
demonstrated. (B) Cells were incubated with or without the indicated agent for 12 h. The cells were fixed for the confocal microscopic detection of
microtubule organization by staining with anti-β-tubulin antibody (green fluorescence) and DAPI (blue fluorescence, for nuclear detection). (C) Cells
were treated in the same condition to (B) but the detection of microtubule organization by staining with anti-γ-tubulin antibody (green fluorescence)
and DAPI (blue fluorescence). Arrowhead, monopolar γ-tubulin staining. Scale bar, 20 μm. (D) Aurora A luminescent kinase assay was performed. The
data are expressed as mean ± SEM of three independent experiments.
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Figure 6 Effect of KUD773 on the expression of Bcl-2 family members and caspases. (A and B) PC-3 cells were incubated in the absence
or presence of KUD773 (3 μM) for various times. Cells were harvested and lysed for the detection of the indicated protein expression by Western
blot. The expression was quantified using the computerized image analysis system ImageQuant (Amersham Biosciences). The data are expressed
as mean ± SEM of three to four independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the control of 100%.
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tion, invasion and angiogenesis through cleavage of
downstream substrates, including growth factors andtheir receptors, extracellular matrix and cytokines [35].
Accordingly, development of inhibitors against MMP-2
and MMP-9 is a potential anticancer strategy. In this
Yu et al. Journal of Biomedical Science  (2015) 22:2 Page 9 of 12study, KUD773 induced a time-dependent down-
regulation of MMP-2 and MMP-9 expression. The effect
was time-correlated with the increased phosphorylation
and acetylation of histone H3 (two responses in mitosis),
but was prior to the production of γ-H2A.X (a DNA dam-
age response) (Figure 7A). The data indicated that theFigure 7 Effect of KUD773 on MMP expression and histone H3 acetyl
or presence of KUD773 (3 μM) for various times (A) or the indicated agen
the indicated protein expression by Western blot. The expression was qu
(Amersham Biosciences). The data are expressed as mean ± SEM of three inde
with the control of 100%.decreased expression of MMP-2 and MMP-9 was related
to the mechanism of mitotic arrest but not through the
DNA-damaged cell death because both camptothecin and
etoposide (two topoisomerase poisons) which could in-
duce DNA damage and cell death did not result in the
down-regulation of MMP-2 and MMP-9 (Figure 7B).ation and phosphorylation. PC-3 cells were incubated in the absence
t for 24 h (B). Cells were harvested and lysed for the detection of
antified using the computerized image analysis system ImageQuant
pendent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 compared
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Tubulin-targeting agents have long been used for clinical
cancer chemotherapy against a wide variety of cancers.
However, the mechanism-related toxicity, such as per-
ipheral neuropathy, limits the therapeutic use of these
agents [3,6]. The present study seeks to solve the prob-
lem by developing novel agents of introducing anti-
Aurora A activity into anti-tubulin agents. The rationale
is based on the strategy that mitotic interrupting agents
always display high selectivity between cancer cells and
normal cells [3,4,9,36]. Both tubulin-targeting and anti-
Aurora A agents are mitotic interrupting agents. Fur-
thermore, dual-effect inhibitors may reserve individual
activities while decrease the toxicity because of the re-
duced concentrations used for reaching similar efficacy.
The flow cytometric analysis of PI staining showed that
KUD773 induced G2/M arrest of the cell cycle and a
subsequent cell apoptosis. The data together with the
dramatic increase of mitotic protein phosphorylation in-
dicated the mitotic arrest other than G2 arrest to
KUD773 action. The cell-based microtubule assembly
assay showed that KUD773, similar to vincristine, inhib-
ited tubulin polymerization and microtubule assembly.
The SRB assay also has been performed to examine the
effect of KUD773 on anti-proliferation in several cancer
cell lines. The GI50 values were 2.2, 2.3, 2.1 and 5.2 in
MDA-MB-231 (breast cancer), A549 (non-small cell
lung cancer), HCT-116 (colorectal cancer) and HT-29
(colorectal cancer), respectively. It is not surprising that
KUD773 is effective against all tested cancer cell lines
because the action target on tubulin is universal in cells,
in particular in proliferating cancer cells.
KUD773 induced a significant increase of Bcl-2 phos-
phorylation, a specific hallmark to tubulin-targeting
agents [37]. It has been suggested that phosphorylated
Bcl-2 fails to dimerize with Bax, leading to augmented
levels of free Bax and acceleration of cell apoptosis [38].
Several studies show that Bcl-2 may bind Raf-1. Further-
more, Raf-1 depletion by geldanamycin inhibits Bcl-2
phosphorylation [37,39,40], suggesting that Raf-1 is a
potential candidate for Bcl-2 phosphorylation. However,
the responsible kinase for KUD773-mediated Bcl-2
phosphorylation needs further investigation.
Cdk1 interacts with cyclin B1 to form a heterodimer
complex. The complex activity is required for the pro-
gression of cell cycle to mitotic prophase and metaphase.
Moreover, it has been identified that Cdk1 activity is re-
sponsible for triggering cell death in certain signaling
cascades under apoptotic stimuli, including exposure to
tubulin-targeting agents [9,36,37]. The entry of cell cycle
into mitosis is controlled by Cdk1 activation through
several steps, including cyclin B1 binding and Cdk1
phosphorylation at Thr161. Moreover, dephosphorylation
of Cdk1 at Tyr15 appears to be a critical step for Cdk1activation during the progression into cell mitosis
[25,41]. The data showed that KUD773 induced the acti-
vation of Cdk1 and mitotic arrest in both PC-3 and DU-
145 cells. These events could guarantee the activation of
apoptotic program because it has been extensively iden-
tified that premature activation of Cdk1 can result in mi-
totic catastrophe after a wide variety of cellular stresses
[9,26,42].
The Aurora kinases, including Aurora A, Aurora B
and Aurora C, are serine/threonine kinases that are im-
plicated with critical processes in cell mitosis [7]. Aurora
A, an oncogenic Aurora kinase, is mainly centrosomal
and localizes to mitotic spindle. It is necessary for
centrosome separation and microtubule assembly [8,9].
Aurora B has been shown to colocalize with end-binding
protein 1 on central spindle during anaphase and on
midbody during cytokinesis, playing a crucial role in
chromosome biorientation, cytokinesis and spindle as-
sembly checkpoint [43,44]. By contrast, much less is
known about the cellular function of Aurora C. How-
ever, recent studies show that overexpression of active
Aurora C in NIH-3T3 stable cell lines leads to tumor
formation when injected into nude mice, showing an
oncogenic activity of active Aurora C [45]. The present
data demonstrated that KUD773 displayed an inhibitory
activity against Aurora A using luminescent kinase assay.
The inhibitory activity was further validated by the ob-
servation that KUD773 induced the formation of mono-
polar spindle because Aurora A was responsible for
centrosome separation. The effect was similar to other
Aurora A inhibitors, such as VX-680 that led to mono-
polar spindle formation in a wide variety of cancer cells
[46]. Of note, KUD773 caused histone H3 phosphoryl-
ation at Ser10. It has been documented that both Aurora
A and Aurora B are able to phosphorylate histone H3
[47]. However, Aurora B is specifically responsible for
the phosphorylation of histone H3 not only at Ser10 but
also at Ser28 that contribute to mitotic chromosome
condensation [44,47,48]. KUD773 showed effective in-
hibition on Aurora A but not Aurora B (data not
shown), explaining that histone H3 phosphorylation still
occurred during KUD773-induced mitotic arrest.
MMPs, zinc-dependent endopeptidases, are capable of
degrading a wide spectrum of extracellular matrix pro-
teins. MMPs are also involved in proteolysis of many
non-matrix substrates, such as cytokines and chemo-
kines [49]. Recently, MMP activity has been known to
play a key role in the cleavage of Fas, leading to an in-
creased resistance to FasL-mediated apoptosis in various
cancer cells [50]. MMPs are, therefore, thought to play a
crucial role on directing several cell functions, such as
cell migration, proliferation, differentiation, apoptosis
and angiogenesis [35,49]. Among this family of mem-
bers, MMP-2 and MMP-9 have been characterized as
Yu et al. Journal of Biomedical Science  (2015) 22:2 Page 11 of 12crucial factors contributing to angiogenesis and tumor
invasion [35]. Moreover, highly metastatic variants of
prostate cancers are revealed to contain relatively high
levels of MMP-2 and MMP-9 [51]. The present study
demonstrated that KUD773 induced a significant down-
regulation of MMP-2 and MMP-9 expression, suggesting
an anti-metastatic potential of KUD773 although this ef-
fect has not been determined in this study. The data also
revealed that the inhibitory effect on MMP expression
levels was related to KUD773-mediated anti-mitotic ac-
tivity. It has been suggested that inhibition of tubulin
polymerization may cause the suppression of genetic
transcription and mRNA instability of both MMP-2 and
MMP-9 [52]. It may explain KUD773-induced down-
regulation of these two MMP members. However, the
underlying mechanism warrants further investigation.
Conclusions
The data suggest that KUD773 induces apoptotic sig-
naling in a sequential manner. It inhibits tubulin
polymerization associated with an anti-Aurora A activ-
ity, leading to Cdk1 activation and mitotic arrest of the
cell cycle that in turn induces Bcl-2 degradation and a
subsequent caspase activation in HRPCs. The inhibitory
activity on the expression of MMP-2 and MMP-9 may
add the anticancer potential of KUD773. Because the
class of compounds with imidazole or thiazole structure
has been reported to display some other activities, such
as inhibition of Akt, p38 MAPK and tyrosine kinase,
the anticancer effect of KUD773 may also attributed to
other undefined mechanisms that warrant further eluci-
dation. However, KUD773 which displays both anti-
tubulin and anti-Aurora A activities is a novel design
for dual-effect inhibitors although its structure needs
further optimization for activity improvement.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CCY carried out all the experiments except for Aurora A luminescent kinase
assay and primary cell culture from human prostate specimens. SPL
participated project design and provided human prostate specimens, JLH
performed primary cell culture from human prostate specimens. JTAH
performed Aurora A luminescent kinase assay, KVK synthesized KUD773 and
provided the compound and JHG supervised experimental design, data
analysis and reviewed manuscript. All authors have read and approved the
final manuscript.
Acknowledgements
We acknowledge the support provided by the National Science Council of the
Republic of China (NSC101-2923-B-002-008-MY3) and the Russian Foundation
for Basic Research (project No. 12-03-92005-HHC-a), M.V. Lomonosov Moscow
State University Program of Development and RAS Programme OXHM 9
“Medicinal Chemistry”. The support by the Center for Innovative Therapeutics
Discovery at National Taiwan University is also acknowledged.
Author details
1School of Pharmacy, National Taiwan University, Taipei, Taiwan.
2Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.3Institute of Biotechnology and Pharmaceutical Research, National Health
Research Institutes, Zhunan, Taiwan. 4Department of Medicinal Chemistry,
Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow,
Russian Federation. 5Institute of Physiologically Active Compounds, Russian
Academy of Sciences, Moscow region, Russian Federation.
Received: 24 August 2014 Accepted: 17 December 2014
References
1. Martin SK, Kamelgarn M, Kyprianou N. Cytoskeleton targeting value in
prostate cancer treatment. Am J Clin Exp Urol. 2014;2:15–26.
2. Martínez-Díez M, Guillén-Navarro MJ, Pera B, Bouchet BP, Martínez-Leal JF,
Barasoain I, et al. PM060184, a new tubulin binding agent with potent
antitumor activity including P-glycoprotein over-expressing tumors.
Biochem Pharmacol. 2014;88:291–302.
3. Schmidt M, Bastians H. Mitotic drug targets and the development of novel
anti-mitotic anticancer drugs. Drug Resist Updat. 2007;10:162–81.
4. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin
Pharmacother. 2002;3:755–66.
5. Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the
management of androgen independent prostate cancer. J Urol.
2003;170:1709–16.
6. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a
review of adverse toxicities and novel delivery strategies. Expert Opin Drug
Saf. 2007;6:609–21.
7. Walter AO, Seghezzi W, Korver W, Sheung J, Lees E. The mitotic serine/
threonine kinase Aurora2/AIK is regulated by phosphorylation and
degradation. Oncogene. 2000;19:4906–16.
8. Bischoff JR, Plowman GD. The Aurora/Ipl1p kinase family: regulators of
chromosome segregation and cytokinesis. Trends Cell Biol. 1999;9:454–9.
9. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis.
Oncogene. 2003;22:9075–86.
10. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of
Aurora-A in hepatocellular carcinoma. Clin Cancer Res. 2004;10:2065–71.
11. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD.
Identification of differentially expressed genes in pancreatic cancer cells
using cDNA microarray. Cancer Res. 2002;62:2890–6.
12. Matarasso N, Bar-Shira A, Rozovski U, Rosner S, Orr-Urtreger A. Functional
analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.
Neoplasia. 2007;9:707–15.
13. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for
the treatment of prostate cancer. Cancer Res. 2006;66:4996–5002.
14. Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, et al.
Multiple genes in human 20q13 chromosomal region are involved in an
advanced prostate cancer xenograft. Cancer Res. 2002;62:6803–7.
15. Anand S, Penrhyn-Lowe S, Venkitaraman AR. Aurora-A amplification
overrides the mitotic spindle assembly checkpoint, inducing resistance to
Taxol. Cancer Cell. 2003;3:51–62.
16. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP,
et al. Aurora-A is essential for the tumorigenic capacity and chemoresistance
of colorectal cancer stem cells. Cancer Res. 2010;70:4655–65.
17. Sun C, Chan F, Briassouli P, Linardopoulos S. Aurora kinase inhibition
downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic
agents. Biochem Biophys Res Commun. 2007;352:220–5.
18. Uemoto H, Yahiro Y, Shigemori H, Tsuda M, Takao T, Shimonishi Y, et al.
Keramamides K and L, new cyclic peptides containing unusual tryptophan
residue from Theonella sponge. Tetrahedron. 1998;54:6719–24.
19. Li CM, Chen J, Lu Y, Narayanan R, Parke DN, Li W, et al. Pharmacokinetic
optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-
benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos.
2011;39:1833–9.
20. Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, et al.
Potential antitumor agents. 37. Synthesis and antitumor activity of
guanylhydrazones from imidazo[2,1-b]thiazolesand from the new
heterocyclic system thiazolo[2’,3’:2,3]imidazo[4,5-c]quinoline. J Med Chem.
2005;48:3085–9.
21. Andreani A, Granaiola M, Locatelli A, Morigi R, Rambaldi M, Varoli L, et al.
Substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)- 2-indolinones and
analogues: synthesis, cytotoxic activity, and study of the mechanism of
action. J Med Chem. 2012;55:2078–88.
Yu et al. Journal of Biomedical Science  (2015) 22:2 Page 12 of 1222. Kudryavtsev KV, Churakov AV, Guh JH. 2-(1H-Imidazol-1-yl)- 4-[3-(trifluoromethyl)
phenyl]-1,3-thiazole. Acta Cryst. 2013;E69:o238.
23. Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM. Antiproliferative
effect in human prostatic smooth muscle cells by nitric oxide donor.
Mol Pharmacol. 1998;53:467–74.
24. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New
colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer
Inst. 1990;82:1107–12.
25. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of
regulation, deregulation and therapeutic targets in cancer. Cell Prolif.
2003;36:131–49.
26. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G.
Cell death by mitotic catastrophe: a molecular definition. Oncogene.
2004;23:2825–37.
27. Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the
activity and subcellular localization of Plk1, a human protein kinase
implicated in mitotic spindle function. J Cell Biol. 1995;129:1617–28.
28. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like
kinases and aurora kinases in cancer. Nat Rev Cancer. 2010;10:825–41.
29. Sarkar T, Nguyen TL, Su ZW, Hao H, Bai R, Gussio R, et al. Interaction of
pseudolaric acid B with the colchicine site of tubulin. Biochem Pharmacol.
2012;84:444–50.
30. Cowley DO, Rivera-Pérez JA, Schliekelman M, He YJ, Oliver TG, Lu L, et al.
Aurora-A kinase is essential for bipolar spindle formation and early
development. Mol Cell Biol. 2009;29:1059–71.
31. Liu Q, Ruderman JV. Aurora A, mitotic entry, and spindle bipolarity. Proc
Natl Acad Sci U S A. 2006;103:5811–6.
32. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and
therapy. Oncogene. 2007;26:1324–37.
33. Cleland MM, Norris KL, Karbowski M, Wang C, Suen DF, Jiao S, et al. Bcl-2
family interaction with the mitochondrial morphogenesis machinery. Cell
Death Differ. 2011;18:235–47.
34. Mellor HR, Rouschop KM, Wigfield SM, Wouters BG, Harris AL. Synchronised
phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active
drugs is JNK-independent and requires a mitotic kinase. Biochem Pharmacol.
2010;79:1562–72.
35. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as
cell surface transducers: outside-in signaling and relationship to tumor
progression. Biochim Biophys Acta. 1825;2012:29–36.
36. Chang WL, Chang CS, Chiang PC, Ho YF, Liu JF, Chang KW, et al. 2-Phenyl-
5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimid-
azole derivative, inhibits growth of human prostate cancer cells by affecting
tubulin and c-Jun N-terminal kinase. Br J Pharmacol. 2010;160:1677–89.
37. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality
(a critical review). Int J Cancer. 1999;83:151–6.
38. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc
Natl Acad Sci U S A. 1995;92:4507–11.
39. Blagosklonny MV, Schulte TW, Nguyen P, Trepel J, Neckers L. Taxol-induced
apoptosis and phosphorylation of Bcl-2 protein involves c-raf-1 and
represents a novel c-Raf-1 signal transduction pathway. Cancer Res.
1996;56:1851–4.
40. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration
dependent. Cancer Res. 1998;58:3620–6.
41. Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the p34cdc2
protein kinase in vertebrates. EMBO J. 1991;10:3321–9.
42. Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1:
linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ.
2002;9:1287–93.
43. Harrison MR, Holen KD, Liu G. Beyond taxanes: a review of novel agents
that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv
Hematol Oncol. 2009;7:54–64.
44. Adams RR, Maiato H, Earnshaw WC, Carmena M. Essential roles of
Drosophila inner centromere protein (INCENP) and Aurora-B in histone H3
phosphorylation, metaphase chromosome alignment, kinetochore disjunction,
and chromosome segregation. J Cell Biol. 2001;153:865–80.
45. Khan J, Ezan F, Crémet JY, Fautrel A, Gilot D, Lambert M, et al.
Overexpression of active Aurora-C kinase results in cell transformation and
tumour formation. PLoS One. 2011;6:e26512.
46. Tyler RK, Shpiro N, Marquez R, Eyers PA. VX-680 inhibits Aurora A and Aurora
B kinase activity in human cells. Cell Cycle. 2007;6:2846–54.47. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, et al. Mitotic
phosphorylation of histone H3: spatio-temporal regulation by mammalian
Aurora kinases. Mol Cell Biol. 2002;22:874–85.
48. Goto H, Yasui Y, Nigg EA, Inagaki M. Aurora-B phosphorylates histone H3 at
serine28 with regard to the mitotic chromosome condensation. Genes Cells.
2002;7:11–7.
49. Van Lint P, Libert C. Chemokine and cytokine processing by matrix
metalloproteinases and its effect on leukocyte migration and inflammation.
J Leukoc Biol. 2007;82:1375–81.
50. Wang WS, Chen PM, Wang HS, Liang WY, Su Y. Matrix metalloproteinase-7
increases resistance to Fas-mediated apoptosis and is a poor prognostic factor
of patients with colorectal carcinoma. Carcinogenesis. 2006;27:1113–20.
51. Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, et al.
Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell
line LNCaP. Immunol Invest. 2011;40:447–64.
52. Liu WH, Chen YL, Chang LS. CIL-102 induces matrix metalloproteinase-2
(MMP-2)/MMP-9 down-regulation via simultaneous suppression of genetic
transcription and mRNA stability. Int J Biochem Cell Biol. 2012;44:2212–22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
